An anti-amyloid antibody drug that reduces amyloid beta proteins in the brain has provided a novel treatment for Alzheimer\u2019s disease. This innovative brain imaging solution for Alzheimer\u2019s disease management can analyze Amyloid-Related Imaging Abnormalities (ARIA), a known side-effect in patients using the anti-amyloid drug. Previously, careful monitoring and management of ARIA was crucial due to the drug\u2019s side effects.<\/p>\n
An Artificial Intelligence (AI) company, Neurophet, specializes in brain diseases. Neurophet has created a new technology that examines ARIA-E (edema), generally detected by T2-FLAIR, and MRI sequence, along with ARIA-H (hemorrhages), mostly recognized by GRE or SWI. To properly observe cortical amyloid beta deposition, an amyloid-PET scan is essential.
\nThe AI technology developed by Neurophet predicts amyloid positivity through Magnetic Resonance (MR) images before conducting amyloid-PET scans. Since amyloid-PET scans are expensive and their use and recompense are severely restricted, the use of MR images for predicting amyloid positivity could offer a cost-effective solution in regards to clinical trials and prognosis of Alzheimer\u2019s.
\n
Neurophet set the stage at the 2023 Alzheimer\u2019s Association International Conference (AAIC) with its cutting-edge brain imaging analysis technology, which can be used in both clinical trials and Alzheimer\u2019s disease drug prescriptions.<\/p>\n
AQUA software, a brain MRI analysis tool, examines brain atrophy observed in neurodegenerative diseases such as Alzheimer\u2019s by measuring cortical amyloid beta deposition, a known causative agent of the disease. Neurophet hopes to bring the products to market side-by-side with new Alzheimer\u2019s disease treatments. The company has invested in research and development focused on ARIA side effects.
\n
<\/p>\n
Jake Junkil Been, CEO of Neurophet, said, \u201cNeurophet\u2019s major products and technologies are expected to be very useful in the process of clinical trials, diagnosis, side effect monitoring, and prognosis observation of Alzheimer\u2019s disease treatment. We are going all out to develop solutions related to Alzheimer\u2019s disease treatment to preemptively target the high-growth Alzheimer\u2019s disease treatment market.\u201d<\/p>\n
______________<\/p>\n
RadParts, a TTG Imaging Solutions Company, is the world\u2019s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.
\n
Written by the digital marketing team at Creative Programs & Systems: https:\/\/www.cpsmi.com\/<\/p>\n","protected":false},"excerpt":{"rendered":"